Psoriatic Arthritis Treatments

Find Psoriatic Arthritis Treatments

Generic Name

Ustekinumab

Brand Names

Ustekinumab-AAUZ, Pyzchiva, Yesintek, Otulfi, Selarsdi, Ustekinumab-aekn, Starjemza, Wezlana, Steqeyma, Ustekinumab-TTWE, Stelara

FDA approval date: September 25, 2009

Classification: Interleukin-12 Antagonist

Form: Injection, Solution

What is Ustekinumab-AAUZ (Ustekinumab)?

SELARSDI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Summary: The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.

Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.

An Observational Study to Assess the Long-term Safety of Ustekinumab Versus Other Biologic Therapies Among Patients With Crohn's Disease and Ulcerative Colitis: A New-User Cohort Study Using the Department of Defense Electronic Health Records Database

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug

Summary: The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

View All Clinical Trials